IKT · Inhibikase Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $10.84M | - | $7.65M | $5.27M | $10.51M | - | $4.19M | $3.08M | $2.75M | - |
| SG&A | $7.38M | - | $5.61M | $5.92M | $5.25M | - | $1.64M | $1.97M | $2.03M | - |
| Total Operating Expenses | $17.84M | - | $12.77M | $10.83M | $14.60M | - | $5.83M | $5.05M | $4.78M | - |
| D&A | $0 | - | $23.7K | $24.2K | $12.7K | - | $6.6K | $6.6K | $6.6K | - |
| Operating Income | ($17.84M) | - | ($12.77M) | ($10.83M) | ($14.60M) | - | ($5.83M) | ($5.05M) | ($4.78M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($16.38M) | - | ($11.93M) | ($9.92M) | ($13.68M) | - | ($5.78M) | ($4.96M) | ($4.65M) | - |
| EPS - Basic | ($0.10) | - | ($0.13) | ($0.11) | ($0.15) | - | ($0.65) | ($0.66) | ($0.73) | - |
| EPS - Diluted | ($0.10) | - | ($0.13) | ($0.11) | ($0.15) | - | ($0.65) | ($0.66) | ($0.73) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $49.57M | $178.80M | $38.27M | $77.74M | $73.44M | $56.50M | $913.4K | $3.09M | $2.35M | $9.17M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.59M | $1.16M | $620.5K | $2.70M | $1.69M | $943.0K | $2.53M | $1.34M | $1.29M | $646.8K |
| Current Assets | $172.18M | $180.11M | $78.54M | $88.79M | $94.16M | $98.45M | $4.19M | $8.60M | $10.81M | $14.21M |
| Total Assets | $173.33M | $181.20M | $79.59M | $88.85M | $94.28M | $98.60M | $4.38M | $8.83M | $11.07M | $14.51M |
| Current Liabilities | $5.71M | $8.30M | $6.70M | $8.80M | $8.55M | $3.73M | $4.91M | $3.70M | $4.23M | $3.44M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $381.8K |
| Total Liabilities | $5.71M | $8.30M | $6.70M | $8.80M | $8.55M | $3.73M | $4.91M | $3.73M | $4.29M | $3.53M |
| Stockholders' Equity | $167.62M | $172.90M | $72.90M | $80.05M | $85.73M | $94.87M | ($530.6K) | $5.10M | $6.78M | $10.98M |
| Retained Earnings | ($159.06M) | ($142.68M) | ($129.95M) | ($118.01M) | ($108.10M) | ($94.42M) | ($82.29M) | ($76.51M) | ($71.55M) | ($66.90M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($12.06M) | - | - | - | ($4.10M) | - | - | - | ($3.87M) | - |
| Investing Cash Flow | ($80.48M) | - | - | - | $21.05M | - | - | - | ($3.31M) | - |
| Financing Cash Flow | $2.90M | - | - | - | $0 | - | - | - | $367.0K | - |
| CapEx | $0 | - | - | - | $0 | - | - | - | - | - |
| Free Cash Flow | ($12.06M) | - | - | - | ($4.10M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.74 | - | - | - | 0.30 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.5% | - | -15.0% | -11.2% | -14.5% | - | -132.0% | -56.2% | -42.0% | - |
| Return on equity | -9.8% | - | -16.4% | -12.4% | -16.0% | - | 1089.0% | -97.3% | -68.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 30.14 | 21.70 | 11.73 | 10.09 | 11.01 | 26.37 | 0.85 | 2.32 | 2.55 | 4.13 |
| Quick ratio | 30.14 | 21.70 | 11.73 | 10.09 | 11.01 | 26.37 | 0.85 | 2.32 | 2.55 | 4.13 |
| Cash ratio | 8.68 | 21.54 | 5.72 | 8.83 | 8.59 | 15.13 | 0.19 | 0.83 | 0.56 | 2.67 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.03 |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.03 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.03 | 1.05 | 1.09 | 1.11 | 1.10 | 1.04 | -8.25 | 1.73 | 1.63 | 1.32 |
| Liabilities / Assets | 0.03 | 0.05 | 0.08 | 0.10 | 0.09 | 0.04 | 1.12 | 0.42 | 0.39 | 0.24 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.7x | - | 2.0x | 2.2x | 2.3x | - | - | 1.8x | 2.0x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | -100.0% | -100.0% | -100.0% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -22.2% | - | -119.1% | -114.5% | -205.2% | - | -22.2% | 18.6% | -1.4% | - |
| Net income growth (YoY) | -19.8% | - | -106.5% | -99.9% | -194.2% | - | -25.7% | 14.2% | -3.8% | - |
| EPS growth (YoY) | 33.3% | - | 80.0% | 83.3% | 79.5% | - | 24.4% | 40.5% | -305.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -193.9% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 95.5% | 82.3% | - | 1470.7% | 1165.1% | 764.2% | - | -73.8% | -73.2% | -47.8% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Inhibikase Therapeutics against the 5 most active filers in the same SIC group.